Hikma Pharmaceuticals (LON:HIK) Stock Price Crosses Above Two Hundred Day Moving Average - Should You Sell?

Key Points

• Hikma Pharmaceuticals shares moved above their 200-day moving average, reaching GBX 1,632 and last trading at GBX 1,620, compared with the moving average of GBX 1,495.66.
• Analysts remain bullish: six analysts rate the stock a Buy, with an average price target of GBX 2,085.83. Recent targets range from GBX 1,870 at Citigroup to GBX 2,100 at Berenberg.
• Company insider Tobias Hestler purchased 7,500 shares for approximately £123,600, while insiders collectively own 22.26% of Hikma’s stock.

Shares of Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of GBX 1,495.66 and traded as high as GBX 1,632. Hikma Pharmaceuticals shares last traded at GBX 1,620, with a volume of 524,176 shares changing hands.

Analysts Set New Price Targets

A number of brokerages recently weighed in on HIK. Citigroup lifted their target price on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the company a "buy" rating in a report on Wednesday, August 12th. Deutsche Bank Aktiengesellschaft restated a "buy" rating and issued a GBX 1,950 target price on shares of Hikma Pharmaceuticals in a research report on Friday, August 7th. Jefferies Financial Group reiterated a "buy" rating and set a GBX 2,025 price objective on shares of Hikma Pharmaceuticals in a research note on Friday, September 25th. Finally, Berenberg Bank upped their price target on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a "buy" rating in a report on Tuesday, August 11th. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Hikma Pharmaceuticals presently has an average rating of "Buy" and an average target price of GBX 2,085.83.

Hikma Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 77.57, a current ratio of 1.98 and a quick ratio of 1.27. The stock's 50 day simple moving average is GBX 1,606.84 and its two-hundred day simple moving average is GBX 1,495.66. The stock has a market cap of £3.35 billion, a price-to-earnings ratio of 9.20, a P/E/G ratio of 2.38 and a beta of 0.66.

Insider Buying and Selling at Hikma Pharmaceuticals

In related news, insider Tobias Hestler acquired 7,500 shares of the company's stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average price of GBX 1,648 per share, for a total transaction of £123,600. Company insiders own 22.26% of the company's stock.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.